David Shaw’s Sage Therapeutics SAGE Stock Holding History

David Shaw’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$568K	–	5196
2021 Q2	$568K	Buy	+10,000	New	+$707K	﹤0.01%	3970
2020 Q3	–	Sell	-25,000	Closed	-$1.04M	–	4116
2020 Q2	$1.04M	Buy	+25,000	New	+$907K	﹤0.01%	2900
2020 Q1	–	Sell	-70,300	Closed	-$5.08M	–	4210
2019 Q4	$5.08M	Hold	70,300	–	–	0.01%	1724
2019 Q3	$9.86M	Hold	70,300	–	–	0.01%	1171
2019 Q2	$12.9M	Hold	70,300	–	–	0.02%	996
2019 Q1	$11.2M	Sell	70,300 -30,000	-30%	-$4.34M	0.01%	1038
2018 Q4	$9.61M	Buy	100,300 +5,000	+5%	+$572K	0.01%	1114
2018 Q3	$13.5M	Hold	95,300	–	–	0.02%	954
2018 Q2	$14.9M	Buy	95,300 +50,300	+112%	+$7.9M	0.02%	879
2018 Q1	$7.25M	Buy	45,000 +15,000	+50%	+$2.55M	0.01%	1184
2017 Q4	$4.94M	Hold	30,000	–	–	0.01%	1501
2017 Q3	$1.87M	Buy	30,000 +20,000	+200%	+$1.57M	﹤0.01%	2083
2017 Q2	$796K	Buy	+10,000	New	+$723K	﹤0.01%	2550

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

David Shaw's SAGE Position: Q3 2025 in Review

David Shaw sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,917,284 shares — an estimated $17.5M sold.

David Shaw first reported a position in SAGE in Q4 2015 and held it in 34 quarters. The position peaked at $190M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

David Shaw reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
David Shaw sold 1,917,284 Sage Therapeutics shares in Q3 2025, an estimated $17.5M.
David Shaw first reported a position in Sage Therapeutics in Q4 2015 and held it in 34 quarters.
David Shaw's Sage Therapeutics position peaked at $190M in Q4 2020.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.